Patent · US Active

Compositions comprising finafloxacin and Tris

US10576088B2 · kind B2 · utility

0Cited by

2References

11Claims

0Family size

Assignee

MerLion Pharmaceuticals Pte. Ltd. · SG

Inventors

Carsten Fischer · Bensheim, DE
Andreas Vente · Berlin, DE
Sven-Eric Wohlert · Berlin, DE

Key dates

Filing date	Oct 9, 2015
Grant date	Mar 3, 2020
Priority date	—
Expiry date	Oct 9, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.